Abstract
Rapamycin, a novel macrolide immunosuppressive drug, is increasingly used as an agent for post-transplant immunosuppression and treatment of autoimmune disease. Rapamycin inhibits mammalian target of rapamycin resulting in delayed wound healing. This delayed wound healing was normalized by treatment with basic fibroblast growth factor. This indicates that basic fibroblast growth factor plays an important and critical role in the rapamycin-induced delayed wound healing process.
| Original language | English |
|---|---|
| Pages (from-to) | 39-44 |
| Number of pages | 6 |
| Journal | Skin Research |
| Volume | 11 |
| Issue number | SUPPL. 17 |
| Publication status | Published - 2012 Mar |
| Externally published | Yes |
Keywords
- Basic fibroblast growth factor
- Cell adhesion molecules
- Inflammatory cells
- Rapamycin
- Wound healing
ASJC Scopus subject areas
- Dermatology
- Infectious Diseases
